Frontiers in Neurology (Jun 2022)

The Clinical Impact of Methotrexate-Induced Stroke-Like Neurotoxicity in Paediatric Departments: An Italian Multi-Centre Case-Series

  • Andrea Santangelo,
  • Emanuele Bartolini,
  • Giulia Nuzzi,
  • Thomas Foiadelli,
  • Alexandre Michev,
  • Tommaso Mina,
  • Irene Trambusti,
  • Valeria Fichera,
  • Alice Bonuccelli,
  • Gabriele Massimetti,
  • Diego G. Peroni,
  • Diego G. Peroni,
  • Emanuela De Marco,
  • Luca Coccoli,
  • Laura Luti,
  • Sayla Bernasconi,
  • Margherita Nardi,
  • Maria Cristina Menconi,
  • Gabriella Casazza,
  • Dario Pruna,
  • Rosamaria Mura,
  • Chiara Marra,
  • Daniele Zama,
  • Pasquale Striano,
  • Pasquale Striano,
  • Duccio M. Cordelli,
  • Roberta Battini,
  • Roberta Battini,
  • Alessandro Orsini

DOI
https://doi.org/10.3389/fneur.2022.920214
Journal volume & issue
Vol. 13

Abstract

Read online

IntroductionStroke-like syndrome (SLS) is a rare subacute neurological complication of intrathecal or high-dose (≥500 mg) Methotrexate (MTX) administration. Its clinical features, evoking acute cerebral ischaemia with fluctuating course symptoms and a possible spontaneous resolution, have elicited interest among the scientific community. However, many issues are still open on the underlying pathogenesis, clinical, and therapeutic management and long-term outcome.Materials and MethodsWe retrospectively analyzed clinical, radiological and laboratory records of all patients diagnosed with SLS between 2011 and 2021 at 4 National referral centers for Pediatric Onco-Hematology. Patients with a latency period that was longer than 3 weeks between the last MTX administration of MTX and SLS onset were excluded from the analysis, as were those with unclear etiologies. We assessed symptom severity using a dedicated arbitrary scoring system. Eleven patients were included in the study.ResultsThe underlying disease was acute lymphoblastic leukemia type B in 10/11 patients, while fibroblastic osteosarcoma was present in a single subject. The median age at diagnosis was 11 years (range 4–34), and 64% of the patients were women. Symptoms occurred after a mean of 9.45 days (± 0.75) since the last MTX administration and lasted between 1 and 96 h. Clinical features included hemiplegia and/or cranial nerves palsy, paraesthesia, movement or speech disorders, and seizure. All patients underwent neuroimaging studies (CT and/or MRI) and EEG. The scoring system revealed an average of 4.9 points (± 2.3), with a median of 5 points (maximum 20 points). We detected a linear correlation between the severity of the disease and age in male patients.ConclusionsSLS is a rare, well-characterized complication of MTX administration. Despite the small sample, we have been able to confirm some of the previous findings in literature. We also identified a linear correlation between age and severity of the disease, which could improve the future clinical management.

Keywords